AMH and Dosing Regimens for Initial IVF Stimulation Protocols
NCT ID: NCT03098199
Last Updated: 2018-04-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
78 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-22
Study Completion Date
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a research study on a hormone in women called anti-mullerian hormone (AMH) an indicator of the amount of egg reserve in the ovaries. The research involves a blood draw to determine the AMH level. This knowledge will help the investigators decide a dosage of gonadotropins, the hormones used to stimulate the production of more than one egg for use in an in vitro fertilization (IVF) cycle. The amount of gonadotropin given has to be tailored to each individual participant. The investigators can use information about the participant and the hormone levels to determine this dosage and the chances of becoming pregnant as a result of IVF treatment. The reason the investigators are doing this research is to find out if basing the gonadotropin dosage solely on the participant's AMH level will give the investigators a better result than the previous method based on age and other hormone levels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins
NCT02237781
Female Infertility
UNKNOWN
PHASE2/PHASE3
Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality
NCT03139474
Infertility, Female
UNKNOWN
PHASE2/PHASE3
Antimullerian Hormone as an Indicator for Ovarian Response
NCT03291860
Infertility, Female
UNKNOWN
Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders
NCT05103228
Infertility
Ovarian Dysfunction
COMPLETED
NA
Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old
NCT01219387
AMH Levels
Inhibin B Levels
IVF Patients Over 38 Years Old
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background / Rationale Anti-Müllerian Hormone (AMH) has been established as a valuable biomarker of ovarian reserve. It is a glycoprotein produced by granulosa cells of the ovary; it regulates the development of the primary follicle while inhibiting further recruitment of other surrounding follicles. Day 3 FSH and basal antral follicle count have traditionally been used to assess ovarian reserve and while they remain excellent predictors of poor ovarian response, they have not been shown to predict IVF success rates. Given the association between AMH and ovarian reserve, it has been proposed that AMH level can be used to predict ovarian response to gonadotropin stimulation and also, IVF success rates. An inverse relationship between AMH and total gonadotropin dosage has previously been demonstrated. As such, the concept of tailoring stimulation protocols to the patient's potential for oocyte production based on AMH level has gained favor. Individualization allows the practitioner to use the minimum dosage of medication required for maximum response, while limiting the risk of ovarian hyperstimulation syndrome. The question becomes how to determine the dosage of medication required for each AMH level and what effect will this have on clinical outcomes?
Hypothesis 1) Knowledge of AMH level used to determine medication dosage at the start of the stimulation cycle will result in a higher oocyte yield at the time of retrieval, higher clinical pregnancy rate, and higher live birth rate.
2\) Knowledge of AMH level used to determine initial medication dosage at the start of the stimulation cycle will result in a fewer number of dosage changes mid-cycle.
3\) Knowledge of AMH level prior to the start of a stimulation cycle will result in the use of a different initial stimulation dose compared to cycles in which the AMH is unknown.
4\) Knowledge of AMH level used to determine medication dosage prior to the start of the stimulation cycle will result in a lower rate of ovarian hyperstimulation syndrome (OHSS). (Defined as \>=20 oocytes/follicles) 5) Knowledge of AMH level used to determine medication dosage prior to the start of the stimulation cycle will result in a lower rate of cancelled cycles.
Methods and Procedures. The AMH level for all patients will be assessed at the initial fertility evaluation for each patient.
Patients will undergo controlled ovarian hyperstimulation (COH) with a GnRH antagonist protocol. They will begin COH on day 3 of their menstrual cycle or they may need to begin with approximately one week of oral contraceptives. After one week, the patients will stop taking oral contraceptives if their ovaries appear quiescent on transvaginal ultrasound and their serum E2 levels are low. These patients will then begin COH three days later. Gonadotropin dosage will be determined at the start of the cycle by AMH level.
Dosages will be adjusted, beginning on the third day of gonadotropins, based on clinical response, determined by serum hormone levels and transvaginal ultrasound of the ovaries throughout the cycle. The patient will begin taking the GnRH antagonist, Ganirelix or Cetrotide, when the lead follicle measures ≥14mm on transvaginal ultrasound. Patients will be triggered with Lupron, hCG, or both when the lead follicle measures ≥20mm on transvaginal ultrasound. All medications are administered via subcutaneous injections.
Transvaginal ultrasound-guided oocyte retrieval will be performed 36 hours after the trigger medication(s) is administered. Cycles with a poor ovarian response, defined as \<3 follicles and/or a peak estradiol level \<600 pg/mL, will be canceled.
Patients will undergo culture day 5 embryo transfer; number of embryos transferred will be according to ASRM guidelines. If the patient exhibits symptoms of OHSS, she will discontinue luteal phase support and will not have an embryo transfer, and all good quality blastocyst mbryos will be cryopreserved. All patients eligible for embryo transfer will continue the luteal phase support protocol until the serum hCG pregnancy test 14 days post-retrieval. If the serum hCG is \<5 mIU/mL, luteal phase support will be discontinued. If the serum hCG is ≥5 mIU/mL, Estrace will continue to be taken until 8 weeks gestation and Endometrin or intramuscular progesterone in oil will continue to be used until 10 weeks gestation. At this point, patient is released to the care of the obstetrician. The patient or the obstetrician will be contacted for pregnancy outcome data.
Hypothesis 1) Knowledge of AMH level used to determine medication dosage at the start of the stimulation cycle will result in a higher oocyte yield at the time of retrieval, higher clinical pregnancy rate, and higher live birth rate.
2\) Knowledge of AMH level used to determine initial medication dosage at the start of the stimulation cycle will result in a fewer number of dosage changes mid-cycle.
3\) Knowledge of AMH level prior to the start of a stimulation cycle will result in the use of a different initial stimulation dose compared to cycles in which the AMH is unknown.
4\) Knowledge of AMH level used to determine medication dosage prior to the start of the stimulation cycle will result in a lower rate of ovarian hyperstimulation syndrome (OHSS). (Defined as \>=20 oocytes/follicles) 5) Knowledge of AMH level used to determine medication dosage prior to the start of the stimulation cycle will result in a lower rate of cancelled cycles.
Methods and Procedures. The AMH level for all patients will be assessed at the initial fertility evaluation for each patient.
Patients will undergo controlled ovarian hyperstimulation (COH) with a GnRH antagonist protocol. They will begin COH on day 3 of their menstrual cycle or they may need to begin with approximately one week of oral contraceptives. After one week, the patients will stop taking oral contraceptives if their ovaries appear quiescent on transvaginal ultrasound and their serum E2 levels are low. These patients will then begin COH three days later. Gonadotropin dosage will be determined at the start of the cycle by AMH level.
Dosages will be adjusted, beginning on the third day of gonadotropins, based on clinical response, determined by serum hormone levels and transvaginal ultrasound of the ovaries throughout the cycle. The patient will begin taking the GnRH antagonist, Ganirelix or Cetrotide, when the lead follicle measures ≥14mm on transvaginal ultrasound. Patients will be triggered with Lupron, hCG, or both when the lead follicle measures ≥20mm on transvaginal ultrasound. All medications are administered via subcutaneous injections.
Transvaginal ultrasound-guided oocyte retrieval will be performed 36 hours after the trigger medication(s) is administered. Cycles with a poor ovarian response, defined as \<3 follicles and/or a peak estradiol level \<600 pg/mL, will be canceled.
Patients will undergo culture day 5 embryo transfer; number of embryos transferred will be according to ASRM guidelines. If the patient exhibits symptoms of OHSS, she will discontinue luteal phase support and will not have an embryo transfer, and all good quality blastocyst mbryos will be cryopreserved. All patients eligible for embryo transfer will continue the luteal phase support protocol until the serum hCG pregnancy test 14 days post-retrieval. If the serum hCG is \<5 mIU/mL, luteal phase support will be discontinued. If the serum hCG is ≥5 mIU/mL, Estrace will continue to be taken until 8 weeks gestation and Endometrin or intramuscular progesterone in oil will continue to be used until 10 weeks gestation. At this point, patient is released to the care of the obstetrician. The patient or the obstetrician will be contacted for pregnancy outcome data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Infertility
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMH<1.5, 300IU Gonal-F + 150 IU Menopur
dosage at 300IU Gonal-F + 150IU Menopur
Group Type
EXPERIMENTAL
300IU Gonal-F
Intervention Type
DRUG
\<1.5 AMH group
150IU Menopur
Intervention Type
DRUG
\<1.5 AMH group
AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur
dosage of 225IU Gonal-F + 75IU Menopur
Group Type
EXPERIMENTAL
225IU Gonal-F
Intervention Type
DRUG
1.6-2.5 AMH group
75IU Menopur
Intervention Type
DRUG
1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur
start dosage of 150IU Gonal-F and 75IU Menopur
Group Type
EXPERIMENTAL
75IU Menopur
Intervention Type
DRUG
1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
150IU Gonal-F
Intervention Type
DRUG
2.6-6.9 AMH group
AMH >=7.0, 75IU Gonal-F+75U Menopur
start dosage of 75IU Gonal-F and 75U Menopur
Group Type
EXPERIMENTAL
75IU Menopur
Intervention Type
DRUG
1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
75IU Gonal-F
Intervention Type
DRUG
\>7.0 AMH group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
300IU Gonal-F
\<1.5 AMH group
Intervention Type
DRUG
150IU Menopur
\<1.5 AMH group
Intervention Type
DRUG
225IU Gonal-F
1.6-2.5 AMH group
Intervention Type
DRUG
75IU Menopur
1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
Intervention Type
DRUG
150IU Gonal-F
2.6-6.9 AMH group
Intervention Type
DRUG
75IU Gonal-F
\>7.0 AMH group
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
follitropin
menotropin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* first cycle of IVF with transfer of fresh embryo
Exclusion Criteria
* use of non-autologous oocytes; prior diagnosis of premature ovarian failure or diminished ovarian reserve; BMI\>= 40; cryopreservation cycles; smokers; use of PGS/PGD; use of surgically retrieved sperm or patients with severe male factor; and oocyte- or embryo-banking cycles
Minimum Eligible Age
25 Years
Maximum Eligible Age
43 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Reproductive Specialists of New York
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda Sung, MD
Role: PRINCIPAL_INVESTIGATOR
Reproductive Specialists of New York
References
Explore related publications, articles, or registry entries linked to this study.
Anderson RA, Nelson SM, Wallace WH. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas. 2012 Jan;71(1):28-33. doi: 10.1016/j.maturitas.2011.11.008. Epub 2011 Nov 26.
Reference Type
BACKGROUND
de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002 Feb;77(2):357-62. doi: 10.1016/s0015-0282(01)02993-4.
Reference Type
BACKGROUND
Freour T, Mirallie S, Colombel A, Bach-Ngohou K, Masson D, Barriere P. Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol (Paris). 2006 Dec;67(6):567-74. doi: 10.1016/s0003-4266(06)73008-6.
Reference Type
BACKGROUND
Gleicher N, Kim A, Weghofer A, Barad DH. Toward a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte. J Clin Endocrinol Metab. 2012 Mar;97(3):995-1004. doi: 10.1210/jc.2011-2403. Epub 2011 Dec 14.
Reference Type
BACKGROUND
Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010 Feb;93(3):855-64. doi: 10.1016/j.fertnstert.2008.10.042. Epub 2008 Nov 30.
Reference Type
BACKGROUND
Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril. 2008 Sep;90(3):737-43. doi: 10.1016/j.fertnstert.2007.07.1293. Epub 2007 Oct 17.
Reference Type
BACKGROUND
Panchal S, Nagori C. Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve. J Hum Reprod Sci. 2012 Sep;5(3):274-8. doi: 10.4103/0974-1208.106340.
Reference Type
BACKGROUND
Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005 Feb;45(1):20-4. doi: 10.1111/j.1479-828X.2005.00332.x.
Reference Type
BACKGROUND
van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002 Dec;17(12):3065-71. doi: 10.1093/humrep/17.12.3065.
Reference Type
BACKGROUND
Biasoni V, Patriarca A, Dalmasso P, Bertagna A, Manieri C, Benedetto C, Revelli A. Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF. Reprod Biol Endocrinol. 2011 Aug 9;9:112. doi: 10.1186/1477-7827-9-112.
Reference Type
BACKGROUND
Choi MH, Yoo JH, Kim HO, Cha SH, Park CW, Yang KM, Song IO, Koong MK, Kang IS. Serum anti-Mullerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clin Exp Reprod Med. 2011 Sep;38(3):153-8. doi: 10.5653/cerm.2011.38.3.153. Epub 2011 Sep 30.
Reference Type
BACKGROUND
Elgindy EA, El-Haieg DO, El-Sebaey A. Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril. 2008 Jun;89(6):1670-6. doi: 10.1016/j.fertnstert.2007.05.040. Epub 2007 Jul 20.
Reference Type
BACKGROUND
Honnma H, Baba T, Sasaki M, Hashiba Y, Oguri H, Fukunaga T, Endo T, Asada Y. Different ovarian response by age in an anti-Mullerian hormone-matched group undergoing in vitro fertilization. J Assist Reprod Genet. 2012 Feb;29(2):117-25. doi: 10.1007/s10815-011-9675-9. Epub 2011 Nov 16.
Reference Type
BACKGROUND
La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007 Mar;22(3):766-71. doi: 10.1093/humrep/del421. Epub 2006 Oct 27.
Reference Type
BACKGROUND
Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005 Oct;112(10):1384-90. doi: 10.1111/j.1471-0528.2005.00670.x.
Reference Type
BACKGROUND
Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, Laing I. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009 Nov;92(5):1586-93. doi: 10.1016/j.fertnstert.2008.08.127. Epub 2008 Oct 18.
Reference Type
BACKGROUND
Singh N, Malik E, Banerjee A, Chosdol K, Sreenivas V, Mittal S. "Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population. J Obstet Gynaecol India. 2013 Aug;63(4):268-72. doi: 10.1007/s13224-012-0318-6. Epub 2013 Feb 22.
Reference Type
BACKGROUND
Wu CH, Chen YC, Wu HH, Yang JG, Chang YJ, Tsai HD. Serum anti-Mullerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet. 2009 Jul;26(7):383-9. doi: 10.1007/s10815-009-9332-8.
Reference Type
BACKGROUND
Alviggi C, Humaidan P, Ezcurra D. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. Reprod Biol Endocrinol. 2012 Feb 6;10:9. doi: 10.1186/1477-7827-10-9.
Reference Type
BACKGROUND
Bosch E, Ezcurra D. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol. 2011 Jun 21;9:82. doi: 10.1186/1477-7827-9-82.
Reference Type
BACKGROUND
Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011 Jan-Feb;17(1):46-54. doi: 10.1093/humupd/dmq034. Epub 2010 Jul 28.
Reference Type
BACKGROUND
Fleming R, Broekmans F, Calhaz-Jorge C, Dracea L, Alexander H, Nyboe Andersen A, Blockeel C, Jenkins J, Lunenfeld B, Platteau P, Smitz J, de Ziegler D. Can anti-Mullerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? Reprod Biomed Online. 2013 May;26(5):431-9. doi: 10.1016/j.rbmo.2012.02.027. Epub 2013 Feb 4.
Reference Type
BACKGROUND
La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 Jan-Feb;20(1):124-40. doi: 10.1093/humupd/dmt037. Epub 2013 Sep 29.
Reference Type
BACKGROUND
Martinez F, Clua E, Carreras O, Tur R, Rodriguez I, Barri PN. Is AMH useful to reduce low ovarian response to GnRH antagonist protocol in oocyte donors? Gynecol Endocrinol. 2013 Aug;29(8):754-7. doi: 10.3109/09513590.2013.801443. Epub 2013 Jun 12.
Reference Type
BACKGROUND
Nakhuda GS, Douglas NC, Thornton MH, Guarnaccia MM, Lobo R, Sauer MV. Anti-Mullerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. Reprod Biomed Online. 2010 Jan;20(1):42-7. doi: 10.1016/j.rbmo.2009.10.009. Epub 2009 Oct 30.
Reference Type
BACKGROUND
Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod. 2007 Sep;22(9):2414-21. doi: 10.1093/humrep/dem204. Epub 2007 Jul 18.
Reference Type
BACKGROUND
Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A, Nardo LG. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011 Sep;26(9):2353-62. doi: 10.1093/humrep/der182. Epub 2011 Jun 13.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
597102-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
NCT05969795
RECRUITING
PHASE1
Real-world Evidence on Follitropin Delta Individual Dosing
NCT05173597
RECRUITING
Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle
NCT00971152
COMPLETED
PHASE3
A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®
NCT02935335
COMPLETED
Optimal Stimulation of Hypo-responders Undergoing in Vitro Fertilization (IVF)
NCT07121751
NOT_YET_RECRUITING
PHASE4
Gonadotropin Type in Ovarian Stimulation
NCT02437032
COMPLETED
PHASE4
The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.
NCT00334425
UNKNOWN
PHASE4
Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells
NCT05330130
COMPLETED
PHASE1
Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination
NCT00374634
COMPLETED
PHASE4
Inhibin B/AFC Ratio for Ovarian Response
NCT06292806
NOT_YET_RECRUITING
The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles
NCT03209687
UNKNOWN
PHASE4
Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles
NCT00669786
COMPLETED
PHASE3
Impact of Three Different Gonadotrophin Regimes on Egg Donation Program
NCT00829075
COMPLETED
PHASE4
Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility
NCT01250821
COMPLETED
PHASE4
Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization
NCT02865681
COMPLETED
NA
Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles
NCT02310919
COMPLETED
PHASE3
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
NCT03071172
UNKNOWN
PHASE3
Is the Concentration of Anti-Muellerian Hormon (AMH) Depending on the Menstrual Cycle?
NCT03398603
COMPLETED
Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women
NCT01340521
COMPLETED
PHASE1/PHASE2
Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients
NCT01206803
COMPLETED
Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study
NCT01921166
COMPLETED
PHASE4
AMH and Pregnancy Outcome in IVF
NCT04512807
UNKNOWN
Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day
NCT02397551
COMPLETED
PHASE4